Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
20.05
30.34
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Pacific Shuanglin Bio pharmacy Co Ltd
Cost of Revenue
Pacific Shuanglin Bio pharmacy Co Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403
|
Cost of Revenue
-¥1.4B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-23%
|
|
|
Beigene Ltd
HKEX:6160
|
Cost of Revenue
-¥2.7B
|
CAGR 3-Years
-77%
|
CAGR 5-Years
-70%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Cost of Revenue
-¥137.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Cost of Revenue
-¥992.7m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Cost of Revenue
-¥5B
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
-33%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Cost of Revenue
-¥27.3B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-57%
|
|
Pacific Shuanglin Bio pharmacy Co Ltd
Glance View
Pacific Shuanglin Bio-pharmacy Co., Ltd. engages in the production and marketing of pharmaceutical products. The company is headquartered in Zhanjiang, Guangdong and currently employs 1,627 full-time employees. The firm's main products are human albumin, intravenous immunoglobulin (pH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus immunoglobulin and rabies immunoglobulin. The firm mainly operates its business in the domestic market.
See Also
What is Pacific Shuanglin Bio pharmacy Co Ltd's Cost of Revenue?
Cost of Revenue
-1.4B
CNY
Based on the financial report for Sep 30, 2024, Pacific Shuanglin Bio pharmacy Co Ltd's Cost of Revenue amounts to -1.4B CNY.
What is Pacific Shuanglin Bio pharmacy Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-23%
Over the last year, the Cost of Revenue growth was -61%. The average annual Cost of Revenue growth rates for Pacific Shuanglin Bio pharmacy Co Ltd have been -15% over the past three years , -28% over the past five years , and -23% over the past ten years .
You don't have any saved screeners yet
